Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Performance

NASDAQ:BPTH opened at $0.95 on Friday. The firm has a fifty day simple moving average of $0.90 and a two-hundred day simple moving average of $1.16. Bio-Path has a 12 month low of $0.59 and a 12 month high of $11.58.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent SEC filing. 5.74% of the stock is owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.